Skip to main content
. 2017 Jul 19;8(35):58847–58864. doi: 10.18632/oncotarget.19375

Figure 8. CIP2A knockdown can overcome lapatinib resistance in BT474/LR cells.

Figure 8

(A) Relative CIP2A levels in stable BT474/LR sublines transfected with control (–) or CIP2A shRNA-encoding (+) lentiviral vectors were analyzed with Western blotting. (B) Survival fractions in control and CIP2A knockdown BT474/LR cells treated with lapatinib for 5 days were measured with an MTS assay. Control and CIP2A knockdown BT474/LR cells were treated with lapatinib (0.03 μM) for 2 weeks and then clonogenic survival was determined by staining colonies with crystal violet. Representative images are shown in (C). The bar graph represents the mean values from three independent experiments (D). Control and CIP2A knockdown cells were treated with lapatinib (3 μM) for 48 hours and apoptosis was detected with a cell death ELISA assay (E) and Western blot analysis of PARP and Caspase-3 cleavage (F). All values are presented as the mean ± S.E. (**p < 0.01).